STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly announced Thursday it is acquiring AtaiBeckley, a biotech developing psychedelic treatments for mental health conditions, to expand its neuroscience medicines portfolio.
- Lilly is paying $2.8 billion in cash upfront, with a potential additional $1 billion tied to development and regulatory milestones.
- AtaiBeckley develops psychedelic-based therapies for mental health — an emerging therapeutic class that has drawn growing pharma investment despite ongoing clinical and regulatory uncertainty.
- Eli Lilly is funding the deal with cash from its booming GLP-1 business, as part of a string of acquisitions aimed at diversifying beyond its obesity and diabetes drug franchise.
Why it matters: With $2.8 billion upfront and a potential $3.8 billion total price tag, Lilly is making one of the pharma industry's largest commitments to psychedelic medicine, a field still working through clinical and regulatory unknowns. The deal illustrates how Lilly is converting GLP-1 windfall profits into aggressive neuroscience diversification — a therapeutic area where it has historically been thin.
